ADVFN - Advanced Financial Network.
HOME» NYSE » A » AGN Stock Price » AGN Stock News

Allergan Share News

 Allergan, Stock Price
AGN Stock Price
 Allergan, Stock Chart
AGN Stock Chart
 Allergan, Stock News
AGN Stock News
 Allergan, Company Information
AGN Company Information
 Allergan, Stock Trades
AGN Stock Trades

Inspire Pharma: Dry-Eye Treatment Didn't Meet Study Endpoints

DOW JONES NEWSWIRES Inspire Pharmaceuticals Inc. (ISPH) said its Prolacria treatment for dry eye met neither the primary nor secondary endpoints in a late-stage trial. Shares fell 7.5% to $6.11 premarket. Shares in its partner in developing the eye drops, Allergan Inc. (AGN), weren't active after closing Wednesday at $61.20. Early data about Prolacria had been discouraging, so the final results won't come as a huge surprise, but the treatment had been one of Inspire's most advanced drugs in its pipeline. Its other advanced drug candidate is denufosol tetrasodium for cystic fibrosis. Inspire focuses on developing treatments for ophthalmic and pulmonary diseases. Chief Executive Christy Shaffer said Inspire has reported the results to Allergan and "will be conducting a thorough review of the program before determining next steps, if any." At the end of the six-week study, Inspire gauged subjects extent of dry eye with a "staining score," in which patterns made by a stain are used to measure damaged cells in the central area of the cornea. It aimed to have a proportion of its subjects receiving Prolacria have a staining score of zero compared to a placebo group, its primary endpoint. It also failed to reduce the staining score by two units compared to the control group, the secondary endpoint. Dry eye occurs when the eye isn't being sufficiently lubricated. In November, the drug company reported a narrower third-quarter loss thanks to double-digit growth in sales. -By Joan E. Solsman, Dow Jones Newswires; 212-416-2291; [email protected]

Stock News for Allergan (AGN)
01/19/201717:26:53Amended Statement of Ownership (sc 13g/a)
01/19/201707:59:00Allergan Announces FDA Approval Of RHOFADE™ (Oxymetazoline H...
01/17/201718:19:00Allergan Admits to Disclosure Violations During Valeant Bid
01/17/201702:01:00Allergan and Gedeon Richter Announce Positive Phase III Results...
01/12/201708:00:00Allergan to Report Fourth Quarter and Full Year 2016 Earnings...
01/10/201703:02:00Valeant Agrees To Sell Dendreon -- WSJ
01/09/201723:49:00Valeant Agrees to Sell Dendreon to Sanpower for $820 Million
01/09/201708:30:00Allergan Enters Parkinson's Disease Through Option Arrangement...
01/09/201708:00:00Allergan Enters Into Licensing Agreement with Assembly Biosciences...
01/09/201708:00:00Allergan Enters Into Licensing Agreement with Assembly Biosciences...
01/06/201716:22:26Current Report Filing (8-k)
01/05/201707:30:00Allergan to Present at Goldman Sachs Healthcare CEOs Unscripted...
01/04/201707:35:00FDA Accepts For Filing Supplemental New Drug Application (sNDA...
01/03/201716:15:00Allergan to Present at 35th Annual J.P. Morgan Healthcare Conference
01/03/201710:31:00EQUITY UPDATE: Rosen Law Firm Announces Filing of Securities...
01/03/201707:35:00Allergan Announces FDA Approval of NATRELLE INSPIRA® SoftTouch...
01/03/201703:03:00After Slower Year, Deal Prospects Set to Brighten -- WSJ
12/30/201610:30:00GPM Reminds Investors of the January 3 Deadline in the Class...
12/30/201605:59:00Will 2017 Be the Year of the Deal?
12/28/201615:42:00January 3 Deadline Alert: Law Offices of Howard G. Smith Reminds...

Allergan and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations